Treatment of Hyponatremic Encephalopathy in the Critically Ill
- PMID: 28704229
- DOI: 10.1097/CCM.0000000000002595
Treatment of Hyponatremic Encephalopathy in the Critically Ill
Abstract
Objectives: Hyponatremic encephalopathy, symptomatic cerebral edema due to a low osmolar state, is a medical emergency and often encountered in the ICU setting. This article provides a critical appraisal and review of the literature on identification of high-risk patients and the treatment of this life-threatening disorder.
Data sources, study selection, and data extraction: Online search of the PubMed database and manual review of articles involving risk factors for hyponatremic encephalopathy and treatment of hyponatremic encephalopathy in critical illness.
Data synthesis: Hyponatremic encephalopathy is a frequently encountered problem in the ICU. Prompt recognition of hyponatremic encephalopathy and early treatment with hypertonic saline are critical for successful outcomes. Manifestations are varied, depending on the extent of CNS's adaptation to the hypoosmolar state. The absolute change in serum sodium alone is a poor predictor of clinical symptoms. However, certain patient specific risks factors are predictive of a poor outcome and are important to identify. Gender (premenopausal and postmenopausal females), age (prepubertal children), and the presence of hypoxia are the three main clinical risk factors and are more predictive of poor outcomes than the rate of development of hyponatremia or the absolute decrease in the serum sodium.
Conclusions: In patients with hyponatremic encephalopathy exhibiting neurologic manifestations, a bolus of 100 mL of 3% saline, given over 10 minutes, should be promptly administered. The goal of this initial bolus is to quickly treat cerebral edema. If signs persist, the bolus should be repeated in order to achieve clinical remission. However, the total change in serum sodium should not exceed 5 mEq/L in the initial 1-2 hours and 15-20 mEq/L in the first 48 hours of treatment. It has recently been demonstrated in a prospective fashion that 500 mL of 3% saline at an infusion rate of 100 mL per hour can be given safely. It is critical to recognize the early signs of cerebral edema (nausea, vomiting, and headache) and intervene with IV 3% sodium chloride as this is the time to intervene rather than waiting until more severe symptoms develop. Cerebral demyelination is a rare complication of overly rapid correction of hyponatremia. The principal risk factors for cerebral demyelination are correction of the serum sodium more than 25 mEq/L in the first 48 hours of therapy, correction past the point of 140 mEq/L, chronic liver disease, and hypoxic/anoxic episode.
Comment in
-
Hyponatremic Encephalopathy.Crit Care Med. 2018 Jan;46(1):e100. doi: 10.1097/CCM.0000000000002775. Crit Care Med. 2018. PMID: 29252963 No abstract available.
-
The authors reply.Crit Care Med. 2018 Jan;46(1):e100-e101. doi: 10.1097/CCM.0000000000002784. Crit Care Med. 2018. PMID: 29252964 No abstract available.
Similar articles
-
Treatment of hyponatremic encephalopathy with a 3% sodium chloride protocol: a case series.Am J Kidney Dis. 2015 Mar;65(3):435-42. doi: 10.1053/j.ajkd.2014.09.021. Epub 2014 Nov 25. Am J Kidney Dis. 2015. PMID: 25465163
-
Therapeutic recommendations for management of severe hyponatremia: current concepts on pathogenesis and prevention of neurologic complications.Clin Nephrol. 1996 Sep;46(3):149-69. Clin Nephrol. 1996. PMID: 8879850 Review.
-
Reinduction of hyponatremia improves survival in rats with myelinolysis-related neurologic symptoms.J Neuropathol Exp Neurol. 1996 May;55(5):594-601. doi: 10.1097/00005072-199605000-00011. J Neuropathol Exp Neurol. 1996. PMID: 8627349
-
Hyponatremic encephalopathy: is central pontine myelinolysis a component?Am J Med. 1992 May;92(5):513-22. doi: 10.1016/0002-9343(92)90748-z. Am J Med. 1992. PMID: 1580298
-
Hyponatremic encephalopathy--some experimental and clinical findings.Folia Neuropathol. 2003;41(1):41-5. Folia Neuropathol. 2003. PMID: 12862395 Review.
Cited by
-
Misconceptions and Barriers to the Use of Hypertonic Saline to Treat Hyponatremic Encephalopathy.Front Med (Lausanne). 2019 Mar 15;6:47. doi: 10.3389/fmed.2019.00047. eCollection 2019. Front Med (Lausanne). 2019. PMID: 30931308 Free PMC article. Review.
-
Thiazide-Associated Hyponatremia and Mortality Risk: A Cohort Study.Kidney Med. 2024 Dec 9;7(2):100941. doi: 10.1016/j.xkme.2024.100941. eCollection 2025 Feb. Kidney Med. 2024. PMID: 39866296 Free PMC article.
-
Risk of Overcorrection in Rapid Intermittent Bolus vs Slow Continuous Infusion Therapies of Hypertonic Saline for Patients With Symptomatic Hyponatremia: The SALSA Randomized Clinical Trial.JAMA Intern Med. 2021 Jan 1;181(1):81-92. doi: 10.1001/jamainternmed.2020.5519. JAMA Intern Med. 2021. PMID: 33104189 Free PMC article. Clinical Trial.
-
Understanding the impact of neurologic complications in patients with cirrhosis.SAGE Open Med. 2019 Feb 28;7:2050312119832090. doi: 10.1177/2050312119832090. eCollection 2019. SAGE Open Med. 2019. PMID: 30834114 Free PMC article. Review.
-
Guidelines for the Acute Treatment of Cerebral Edema in Neurocritical Care Patients.Neurocrit Care. 2020 Jun;32(3):647-666. doi: 10.1007/s12028-020-00959-7. Neurocrit Care. 2020. PMID: 32227294 Free PMC article.
Publication types
MeSH terms
Substances
LinkOut - more resources
Full Text Sources
Other Literature Sources
Miscellaneous